Large population-based study suggests no increased major malformation risk following maternal first trimester atomoxetine use

A collaborative of researchers from Nordic countries and the US have published a population-based comparative cohort study including approximately 2.4 million pregnancies ending in live births in Denmark, Iceland, Norway, and Sweden (2003-2017) and approximately 1.8 million in the US, investigating the risk of major malformation following maternal first trimester atomoxetine use. More information can be found here. Photo by […]
» Read more